SNV1521 in Participants With Advanced Solid Tumors

Summary

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Eligibility

Inclusion Criteria:

* Advanced or metastatic solid tumor malignancy
* Evaluable or Measurable disease (RECIST 1.1 Criteria).
* ECOG Performance Status 0 or 1.
* Life expectancy \> 3 months

Exclusion Criteria:

* History of other malignancy within the past 2 years
* Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia
* Significant cardiovascular disease within 6 months
* Significant gastrointestinal disease
* HIV infection with a CD4+ T-cell count \< 200 cells/μL and/or a detectable viral load
* Liver dysfunction

Conditions2

Interventions5

Locations5 sites

Find trials near these locations

Related trials

• A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer — Celgene
• AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) — AstraZeneca
• Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response — Canadian Cancer Trials Group
• Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer — SWOG Cancer Research Network
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial — Mayo Clinic
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors — DualityBio Inc.
• Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer — Amgen
• An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) — Novartis Pharmaceuticals

Browse More Trials